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In this study, we have demonstrated for the first time by using U 46619, a stable analogue of thromboxane A2 (TXA2), that TXA 2 exerts a cell 
proliferative ffect on HeLa cells which is mediated by specific TXA 2 receptors, inasmuch as the cell proliferation could be dose-dependently 
suppressed by TXA 2 receptor antagonist BM 13177. The investigation of the phospholipase C pathway by U 46619 and prostaglandin H2 (PGH2) 
in the presence and absence of BM 13177 in cells with or without pertussis toxin pretreatment, aswell as radioligand receptor binding studies, 
revealed that, in contrast o TXA 2 receptors on human platelets, where TXA 2 and PGH2 share the same receptor binding sites, HeLa cells possess 
distinct receptors for TXA: and PGH 2. 
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1. INTRODUCTION 
There exists plenty of evidence that growing tumours 
synthesize icosanoids ([1], and references therein) and 
that endogenously produced eicosanoids participate in 
the modulation of tumour growth [2-6] and metastasis 
[4,7]. In addition, it has been reported that TXA2 is 
preferentially formed during tumour growth in animal 
and humans [8]. The recent finding that TXA 2 synthe- 
tase activity is increased in growing tumours of human 
breast [9] provided more support for the specific role of 
TXA 2 in tumour growth. 
In the present paper, we report for the first time that 
the stable analogue of TXA2, U 46619, accelerates cell 
proliferation in HeLa cell cultures through a specific 
TXA 2 receptor. Furthermore, this TXA: receptor is ap- 
parently distinct from the TXA 2 receptor on human 
platelets. 
2. MATERIALS AND METHODS 
2.1. Materials 
Eicosanoids and U 46619 were purchased from Cayman Chemicals, 
Ann Arbor, USA. Indomethacin, FURA-2/AM were supplied by 
Sigma, Germany, and pertussis toxin by Calbiochem, Germany. So- 
dium meclofenamate was a gift from Warner Lambert, Ann Arbor, 
USA, and the TXA z receptor antagonist, BM 13177, a gift from Dr. 
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Stegmeier f om Boehringer, Mannheim, Germany. SQ 29548 was sup- 
plied by Cayman Chemicals, Ann Arbor, USA. Radiolabeled com- 
pounds were purchased from Amersham, Germany. 
2.2. Cultivation oj HeLa cells" 
HeLa cells were cultured in Minimum Eagle's Medium (MEM), 
supplemented with 10% fetal calf serum (FCS), 1% L-Gln (200 mM), 
0.5% penicillin (10 000 U/ml) and 0.5% streptomycin (10 000/lg/ml) 
at 37°C in an incubator (5% CO2). Confluency was obtained in 48 h. 
Cells were obtained as single-cell suspensions by rinsing the mono- 
layers with phosphate buffered saline (PBS) without Ca 2+ or Mg 2÷ 
before trypsinizing with trypsin/EDTA (0.0510.02%, w/w) for 5 min at 
37°C. Cells were washed twice with PBS, resuspended in MEM and 
supplemented with FCS, e-Gin and penicillin/streptomycin as above. 
The viability of cells was -> 96%. 
2.3. Cell proliJeration assay 
The influence of different effectors on tumour cell proliferation was 
assayed by means of [3H]thymidine (sp. act. 20.1 Ci/mmol) uptake for 
6 h at 37°C in an incubator. 
2.4. Radioligand receptor binding assay 
Cell suspensions were obtained as described above and adjusted to 
a density of 2 x 10 6 cells/ml medium. Aliquots (50/A) of the labeled 
TXA 2 analogue, [3H]U 46619 (sp. act. 12.1 Ci/mmol), and unlabeled 
compounds, e.g. U 46619, TXB2, PGH2 (prostaglandin H2), 11-dehy- 
dro-TXB2, and PGE2 were added to 1 ml of cell suspension (pH 7.4) 
to obtain concentrations of various substances in the suspension be- 
tween 1 nM and l0/~M. Incubation was carried out for 1 h at 37°C 
in an incubator. The reaction vials were then centrifuged at 100 x g 
for 5 min, the pellet was washed twice and gently resuspended in 500 
/A PBS. The radioactivity was counted in a scintillation counter (Beck- 
man, USA). 
Specific binding was determined as the difference between the 
amount of [3H] U 46619 bound to the cells in the absence and presence 
of 10 ¢tM U 46619. All experiments were performed in triplicate. 
2.5. Measurement of intracellular Ca 2+ [Ca2+]i 
Intracellular Ca -,+ in HeLa cells was measured as described [10]. 
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Briefly, HeLa cells (5 x lo6 cells/ml) were incubated with 5 PM 
FURA-Z/AM for 45 min at room temperature. After washing, cells 
were resuspended in PBS. The cells were then challenged with various 
stimuli as indicated in section 3. The fluorescence was measured in a 
Hitachi F-4000 s~ctrophotometer using excitation and emission 
wavelengths at 340 nm and 505 nm, respectively. Concentrations of 
[Ca”], were calculated as described elsewhere [l 11. 
3. RESULTS AND DISCUSSION 
Upon treatment with the TXA, analogue, U 46619, 
freshly cultured HeLa cells demonstrated an enhanced 
cell proliferation dose-dependently as measured by 
[3H]thymidine uptake (Fig. 1A). At a concentration of 
1 ,uM almost 145% of cell proliferation was achieved. 
Moreover, the proliferative effect of U 46619 was not 
imitated by other TXA, degradation products and pro- 
stanoids, particularly PGH,, which shares several prop- 
erties of TXA, related to platelet functions (12]. 
Considering the recent finding that the growing 
breast tumours show increased activity of TXA, synthe- 
tase [9], one would expect the suppression of tumour 
growth by successful application of TXA, inhibitors in 
vitro and in vivo. Our results with inhibitors of cycloox- 
ygenase enzyme, shown in Fig. lB, do not support the 
previous reports [7]. Whereas indomethacin and sodium 
meclofenamate were unable to inhibit cell proliferation, 
even at a concentration of 20pM, the proliferative effect 
of U 46619 could be suppressed dose-dependently by 
the TXAz receptor antagonists, BM 13177 (IC,, = 0.5 
PM) and SQ 29548 (IC,” = 0.92 PM). This gives a clear 
cut evidence that U 46619 exerts a receptor-mediated 
cell proliferative effect on HeLa cells. Furthermore, it 
explains why treatment of tumour cells with cyclooxy- 
genase inhibitors did not prevent the cell proliferation, 
since these inhibitors were incapable of achieving a 
complete suppression of cellular TXA, synthesis [13]. 
Consequently, a residual TXAz synthesis is sufficient 
for receptor-mediated tumour cell proliferation. 
U 46619 has also been shown to stimulate phospho- 
lipase C (PLC) via receptor G-protein coupling in sev- 
eral cell types [14,15]. Fig. 2A shows the effect of U 
46619 on the release of [Ca”‘], in HeLa cells. A rapid 
and transient release of [Ca”], was observed when cells 
were challenged with U 46619. The release of [Ca”], was 
dose dependent and could be suppressed by pretreat- 
ment of cells with 10 PM BM 13177 (Fig. 2A, inset and 
lower panel). Suppression of [Ca2+], was also obtained 
when HeLa cells were pretreated with pertussis toxin for 
90 min at 37°C (Fig. 2B), suggesting the involvement of 
a G-protein. This indicates that the TXA, receptors on 
HeLa cells are apparently distinct from TX& receptors 
on human platelets, inasmuch as the platelet TXA, re- 
ceptors are coupled to a pertussis toxin-insensitive G- 
protein [16,17]. 
Surprisingly, HeLa cells which were already chal- 
lenged with PGH,, were still capable of releasing [Ca”li 
by treatment with U 46619 (Fig. 3A). Again, whereas 
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Fig. 1. (A) Effect of U 46619 and other prostanoids on the [~H]thymid- 
ine incorporation by HeLa cells. Values are expressed as a mean of 
7 separate cultures. (B) Effect of cyclooxygenase inhibitors and 
TXA, receptor antagonists on the [‘Hlthymidine incorporation by 
HeLa cells. Values are expressed as a mean of 7 separate cultures. 
pretreatment of HeLa cells with 1 FM BM 13 177 signif- 
icantly suppressed the U 46619-induced [Ca”], release, 
no inhibitory effect of BM 13 177 was observed on the 
PGH,-induced [Ca”*], release (Fig. 3B), suggesting dis- 
tinct receptor binding sites for TXA, and PGH,. 
Fig. 4 shows the radioligand binding experiments 
with [3H]U 46619. Whereas increasing concentrations of 
unlabeled U 46619 blocked the specific binding of 13H]U 
46619, none of the degradation products of TXA, or 
other prostanoids effectively altered the binding of 
[lH]U 46619. PGH,, which shares chemical identity 
with TXA,, did partially block [3H]U 46619 binding, 
albeit at very high concentrations (not shown). 
We, therefore, conclude that TXA, exerts a cell pro- 
liferative effect on HeLa cells which is mediated via 
specific TXA, receptors and can be totally blocked by 
TXA, receptor antagonists. In addition, we found that, 
in contrast to TXA, receptors on platelets, the receptors 
on HeLa cells are not shared by PGH, and are coupled 
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Fig. 2. (A) Effect of U 46619 on the release of [Ca”], in HeLa cells. The tracing represents 1 of 5 separate experiments with identical results. (Inset) 
Dose-dependent inhibition of [Ca”], by BM 13177. Values are expressed as mean k S.E.M. of 3 separate experiments. (Lower panel) Inhibition 
of [Ca*+], by 1 PM BM 13177. The tracing represents I of 5 separate experiments with identical results. (B) Effect of pertussis toxin on the U 
46619-induced release of [Ca”],. The tracing represents 1 of 3 separate experiments with identical results. 
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Fig. 3. Evidence for distinct binding sites of U 46619 and PGHz in HeLa cells for the release of [Ca”], (A and B). The tracing represents 1 of 3 
separate experiments with identical results. 
101 
Volume 316, number 1 FEBS LETTERS January 1993 
110 - 
100 
c 
8 
"6 80 
60 
D 
"B 40 
8' 
20 
IZI 
0 I I I I I 
0 10 "9 10 -8 10 -7 10 -6 
[U] 
Fig. 4. Specific binding of [3tt]U 46619 and other prostanoids toTXA~ 
receptor binding sites. Results are expressed as a mean of 4 separate 
experiments with triplicate determinations. 
to PLC via a pertussis toxin-sensitive G-protein. As a 
consequence of our data, we suggest hat an additional 
classification of tumours between TXA 2 receptor-posi- 
tive and TXA 2 receptor-negative ones in analogy to 
estrogen/progesterone receptor-positive and estrogen/ 
progesterone-negative tumours should be introduced. 
This may have far reaching implications for a therapeu- 
tic approach for prevention of tumour growth, inas- 
much as a number of TXA2 receptor antagonists have 
been developed in the past few years and many of them 
are already available on the market. 
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